Purple Biotech (PPBT)
(Delayed Data from NSDQ)
$0.35 USD
-0.02 (-5.90%)
Updated Jul 22, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PPBT 0.35 -0.02(-5.90%)
Will PPBT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PPBT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PPBT
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher
PPBT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PPBT
Purple Biotech files to sell 11.66M American Depositary Shares for holders
Purple Biotech Eyes Key 2024 Milestones
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit